CTCagatay Taskiran

Cagatay Taskiran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cagatay Taskiran has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predicting the Unpredictable: Development and External Validation of the GO SOAR Surgical Risk Calculator for Data-Driven Predictions of Surgical Complications in Gynaecological Oncology Surgery

    by Faiza Gaba, Oleg Blyuss, Janna G. Oganezova, Giulia Pellecchia, Stefano Restaino, Cristian Dell’Acqua, Fabio Martinelli, Naia Seminario, Eloi Sirvent, Martina Aida Angeles, et al.

    Background/Objectives: Universal surgical risk calculators are not validated for use and poorly predict postoperative morbidity and mortality for women undergoing gynaecological oncology surgery. This adversely affects communication of risk resulting in poorly informed decisions and missed opportunities for medical optimization to mitigate risk preoperatively. We present the development and external validation of our novel GO SOAR surgical risk calculator for use to preoperatively predict postoperative thirty-day surgical morbidity and mortality in relation to gynaecological oncology surgeries. Methods: New logistic regression models were developed using the GO SOAR1 training cohort (n = 1811) and externally validated in an independent prospective cohort (n = 416) for two outcomes: thirty-day postoperative mortality (alive versus dead) and thirty-day postoperative morbidity (any complication (Clavien–Dindo I–V) versus none). Performance of the GO SOAR models was compared against established all-purpose surgical risk calculators (SORT/POSSUM/P-POSSUM/NSQIP). Model discrimination was assessed with sensitivity calculated at a clinically significant prespecified specificity threshold of 90%. Results: For mortality, AUROC was 0.752 (95% CI 0.570–0.935) for GO SOAR full and 0.795 (95% CI 0.660–0.930) for GO SOAR condensed; corresponding sensitivities at 90% specificity were 57.1% and 42.9%. For morbidity, AUROC was 0.698 (95% CI 0.641–0.755) and 0.703 (95% CI 0.646–0.760) for the full and condensed models, respectively, with sensitivities of 30.4% and 32.1% at 90% specificity. Conclusions: The GO SOAR model using a data-driven, gynaecological-oncology-specific approach at 90% specificity, achieved the highest observed sensitivity among the evaluated calculators. Accurate surgical risk predictions are crucial for major oncological surgery, where complications can diminish quality of life and affect long-term cancer survival. A model such as the GO SOAR surgical risk calculator that uses readily available preoperative data, regardless of income setting, is essential in reducing global disparities in surgical outcomes.


  • Open Access

    Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer

    by Hakan Özçelik, Nazan Demir, Melisa Eryaşar, Oğuz Çelebi, Erdem Sünger, Burçin Çakan Demirel, Jamshid Hamdard, Özgür Açıkgöz, Burak Giray, Doğan Vatansever, et al.

    Background/Objectives: The 2023 revision of the International Federation of Gynecology and Obstetrics (FIGO) staging system redefines endometrial cancer staging by integrating histopathological and molecular parameters into conventional anatomic assessment. We aimed to quantify stage migration following reclassification from FIGO 2009 to FIGO 2023, to evaluate its impact on survival, and to identify independent prognostic determinants within this restaged cohort. Methods: In this two-center retrospective cohort study, 291 patients with histologically confirmed endometrial cancer were restaged according to both FIGO 2009 and FIGO 2023 systems. Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan–Meier method, and independent prognostic determinants were identified through multivariable Cox proportional hazards modeling. Results: Application of FIGO 2023 resulted in stage migration in 32.0% of patients, with 30.6% upstaged and 1.4% downstaged. Upstaged patients demonstrated significantly worse PFS and OS compared with downstaged patients and patients without stage change (p < 0.001 for both). Notably, among patients initially classified as FIGO 2009 stage I, 38% were reassigned to a higher stage and exhibited a marked survival disadvantage (p < 0.001). In multivariable analysis, advanced age and positive surgical margins independently predicted both poorer PFS and OS, while lymphovascular space invasion (LVSI) independently predicted inferior PFS. The association with positive surgical margins, however, likely reflected concurrent advanced-stage disease. Conclusions: The FIGO 2023 staging system results in substantial stage redistribution in endometrial cancer and provides clearer survival discrimination, particularly by identifying previously unrecognized high-risk subgroups within early-stage disease. The significant survival disadvantage observed among upstaged patients indicates that the revised system may more accurately reflect biologically driven risk stratification. However, stage migration was not independently associated with survival after adjustment for its constituent pathological factors.


  • Open Access

    Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009)

    by Tugan Bese, Sait Sukru Cebi, Salih Taskin, Cagatay Taskiran, Dogan Vatansever, Firat Ortac, Nedim Tokgozoglu, Hasan Turan, İlKer Kahramanoglu, Mete Gungor, et al.

    Bese T, et al. J Gynecol Oncol. 2025 Oct;37:e23. https://doi.org/10.3802/jgo.2026.37.e23

  • Open Access

    Minimally invasive pelvic exenteration: a safe alternative or a surgical challenge? A propensity score matched analysis from the COREPEX study

    by Matteo Loverro, D. Querleu, Giulio Ricotta, Diana Giannarelli, Mihai Emil Capilna, Santiago Domingo Del Pozo, Vito Chiantera, Huseyin Akilli, David Cibula, Zoltan Novak, et al.

    ObjectiveTo compare the oncologic and perioperative outcomes of minimally invasive pelvic exenteration versus the conventional open approach in patients with gynecologic malignancies.MethodsThis was an international, multicenter, retrospective study including patients with cervical, vaginal, vulvar, or endometrial cancer who underwent anterior or total pelvic exenteration between January 2005 and March 2023. A propensity score matching(PSM) analysis was performed to reduce allocation bias. The primary endpoint was recurrence-free survival, while cancer-specific survival(CSS) and perioperative outcomes were evaluated as secondary endpoints.ResultsA total of 862 patients were analyzed, of whom 83 (9.6%) underwent minimally invasive surgery. After PSM, recurrence-free survival was comparable between the two groups (median 19 vs. 11 months, p=0.262), as was cancer-specific survival (CSS) (median 46 vs. 27 months, p=0.770). In multivariate analysis, positive surgical margins were independently associated with both shorter recurrence-free(HR 1.668, p<0.001) and cancer-specific survival (HR 1.591, p=0.004). Total pelvic exenteration was associated with reduced recurrence free survival(HR 1.290, p=0.020), while performing pelvic exenteration in the recurrent setting (HR 1.972, p=0.042) and tumor diameter greater than 5 cm (HR 1.412, p=0.013) were associated with shorter cancer specific survival. The minimally invasive approach resulted in significantly lower blood loss (700 versus 500ml, p<0.001) and shorter hospital stay (17 versus 12 days: p=0.006), although with longer operative time(360 versus 512 minutes, p<0.001).ConclusionIn this large, multicenter, propensity score-matched analysis, minimally invasive pelvic exenteration showed no statistically significant difference in oncologic outcomes compared with the traditional open approach, while providing some perioperative advantage. However, larger scale studies higher power would be necessary to conclude about safety and improvement in quality of life of the minimally invasive approach in this setting.